A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - Dec 15, 2023 - P2 | N=40 | Active, not recruiting | Sponsor: Endeavor Biomedicines, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|